Provided by Tiger Trade Technology Pte. Ltd.

Health Care Select Sector SPDR Fund

165.36
-0.3000-0.18%
Post-market: 165.360.00000.00%19:59 EDT
Volume:6.50M
Turnover:1.08B
Market Cap:42.94B
PE:-11.63
High:167.13
Open:166.83
Low:165.11
Close:165.66
52wk High:176.60
52wk Low:133.73
Shares:259.67M
Float Shares:259.67M
Volume Ratio:0.83
T/O Rate:2.51%
Dividend:2.53
Dividend Rate:1.53%
EPS(TTM):-14.2170
EPS(LYR):-14.2170
ROE:-9.22%
ROA:1.03%
PB:1.25
PE(LYR):-11.63

Loading ...

Man Group PLC : Form 8.3 - Spire Healthcare Group Plc

GlobeNewswire
·
Sep 10

HSBC Adjusts Price Target on Eli Lilly and Co. to $940 From $850, Keeps Reduce Rating

MT Newswires Live
·
Sep 10

Epsilon Healthcare Director Alan Beasley Boosts Shareholding via On-Market Purchases

TIPRANKS
·
Sep 10

Bamboos Health Care Sets September Board Meeting for Annual Results and Dividend Consideration

TIPRANKS
·
Sep 10

Health Care Roundup: Market Talk

Dow Jones
·
Sep 10

XRP Healthcare Goes Offline After Top Ex-Ripple Engineers Call Out 'Red Flags'

utoday
·
Sep 10

Table: CHC Healthcare Group Aug Rev Nt$327.6m vs Nt$283.8m

Dow Jones
·
Sep 10

Private Equity Firm TPG Explores Sale of Healthcare Software Company Lyric, Potential Valuation at $5 Billion

Stock News
·
Sep 10

Top Executive Makes Bold Move With Major Healthcare Realty Trust Stock Sale

TIPRANKS
·
Sep 10

Ramsay Health Care (RMSYF) Gets a Hold from Citi

TIPRANKS
·
Sep 10

Citi Remains a Hold on Sonic Healthcare Limited (SHL)

TIPRANKS
·
Sep 10

EBOS Group Limited (EBO) Gets a Buy from Citi

TIPRANKS
·
Sep 10

Positive Report for Fisher & Paykel Healthcare Corporation Limited (FSPKF) from Citi

TIPRANKS
·
Sep 10

Health Care Down, but not by Much, on Defensive Bias - Health Care Roundup

Dow Jones
·
Sep 10

Sabra Health Care initiated with an Outperform at Huntington

TIPRANKS
·
Sep 10

Health Care Roundup: Market Talk

Dow Jones
·
Sep 10

HCA Healthcare Inc. Stock Climbs 4.9%, Outperforms Peers

Dow Jones
·
Sep 10

Oruka Therapeutics to Attend the 2026 Morgan Stanley Global Healthcare Conference

GlobeNewswire
·
Sep 10

COMPASS Pathways: Strong Phase 3 TRD Data, Differentiated Positioning Support Unchanged $24 Price Target and Buy Rating

TIPRANKS
·
Sep 10

'Cut Points' for 2027 Medicare Advantage Plans Look Neutral to Positive, Analysts Say

Reuters
·
Sep 10